Обзор работ, посвященных В-клеточному хроническому лимфолейкозу, представленных на конференции в Лугано

1. Enjuanes A., Benavente Y., Bosch F. et al. Polymorphisms inapoptotis and immunoregulatory relatedgenes are associated with an increased risk of chronic lymphocytic leukemia (CLL). Abstract book of the 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. Abstr 21.

2. Ghia P., Dagklis A., Fazi C. et al. Striking differences in the ig repertoire between cll and mbl: implications for the pathogenesis of the disease. Abstract book of the 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. Abstr 59.

3. Kienle D., Benner A., Laeufle C. et al. Quantitative gene expression analysis of surrogate markers for genetic risk groups and survival in clld. Abstract book of the 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. Abstr 23.

4. Haferlach C., Dicker F., Schnittger S. et al. New insights into genetics of cll based on chromosome banding analysis. Abstract book of the 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. Abstr 373.

5. Mead G., Harding S., Holder R. et al. Abnormal serum free light chain ratios are associated with poor survival in patients with chronic lymphocytic leukaemia. Abstract book of the 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. Abstr 025.

6. Perdigao C., Cabral M.J., Costa N. et al. Prognosis factors in CLL: is serum free light chain ratio a new biological marker? Abstract book of the 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. Abstr 410.

7. Meuleman N., Stamatopoulos B., Azerad M. et al. Doubling time of soluble CD23 (sCD23DT): a powerful independent prognostic factor for stage a untreated chronic lymphocytic leukemia patients (CLL). Abstract book of the 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. Abstr 22.

8. Mainou-Fowler T., Porteous A., Nicolle A. et al. CD31 density is a new risk factor for patients with b-cell chronic lymphocytic leukaemia. Abstract book of the 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. Abstr 370.

9. Bosch F., Muntanola A., Villamor N. et al. Interim results of the combination rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) followed by rituximab maintenance in previously untreated chronic lymphocytic leukemia (CLL). Abstract book of the 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. Abstr 377.

10. Niederle N., Balleisen L., Heit W. et al. Bendamustine vs. Fludarabine as secondline treatment for patients with chronic lymphocytic leukemia - first interim results of a randomized study. Abstract book of the 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. Abstr 379.

11. Elter T., James R., Wendtner C.M. et al. Treatment of patients with relapsed/refractory cll using a combination of fludarabine, cyclophosphamide and alemtuzumab: first safety analysis of the CLL2L trial of the german CLL study group. Abstract book of the 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. Abstr 378.

12. Byrd J., Castro J., Flinn I. et al. Lumiliximab in combination with FCR for the treatment of relapsed chronic lymphocytic leukemia (CLL): results from a phase I/II multicenter study. Abstract book of the 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. Abstr 145.

13. Pathan N., Estrellado A., Ranuio-Kelley J. et al. Clinical activity of lumiliximab in combination with fcr is independent of ZAP 70 expression on chronic lymphocytic leukemia cells. Abstract book of the 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. Abstr 415.

14. Tangri S., Estrellado A., Byrd J. et al. Immunophenotypic characterization of peripheral blood cells from relapsed chronic lymphocytic leukemia patients treated with lumiliximab in combination with FCR. Abstract book of the 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. Abstr 414.

15. Stamatopoulos B., Meuleman N., Martiat P. et al. The histone deacetylase inhibitor valproic acid increases chemosensitivity to several drugs, induces apoptosis, and can inhibit proliferation of chronic lymphocytic leukemia cells. Abstract book of the 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. Abstr 381.

16. Oliveira A., Leon A., Varela R. et al. Autologous stem cell transplantation (ASCT) in 72 patients with small lymphocytic lymphoma (SLL): the spanish experience. Abstract book of the 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. Abstr 383.

17. Dreger P., Stilgenbauer S., Boettcher S. et al. A prospective multicenter trial on nonmyeloablative allogeneic stem cell transplantation (NST) for poor-risk chronic lymphocytic leukemia (CLL): FINAL results of the GCLLSG CLL3X study. Abstract book of the 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. Abstr 60.

18. Zeis M. Humoral immune responses against the immature laminin receptor protein show prognostic significance in patients with chronic lymphocytic leukemia. Abstract book of the 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. Abstr 411.

19. Rossi D., Capello D., Cerri M. et al. Molecular and clinical prediction of diffuse large b-cell lymphoma (DLBCL) arising in the context of chronic lymphocytic leukemia (CLL). Abstract book of the 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. Abstr 375.

20. Rath J.C., Geisler C., Christiansen C.B. et al. Epstein-Barr virus reactivation is a potentially fatal complication in CLL patients with poor prognostic biological markers and fludarabine refractory disease. Abstract book of the 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. Abstr 382.